<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02447133</url>
  </required_header>
  <id_info>
    <org_study_id>Topcon 001-2015</org_study_id>
    <nct_id>NCT02447133</nct_id>
  </id_info>
  <brief_title>TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro</brief_title>
  <official_title>TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topcon Medical Systems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topcon Medical Systems, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to validate the TopQ cutoff scores, which have been previously
      determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Scans with a TopQ score below the optimum cut-off should be considered to be poor or
      unacceptable quality, and scans with a TopQ score above the cut-off should be considered good
      or acceptable quality. The study will evaluate the predetermined cut-off values by
      investigating measurement variability of scans.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TopQ Cut Off</measure>
    <time_frame>1 hour</time_frame>
    <description>To validate the values of the predetermined TopQ score by showing the variability above and below the TopQ score of 25 for 12x9 Wide, 28 for 6x6 Macula, and 30 for 6x6 Disc scans.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Subjects Presenting With Normal Eyes</condition>
  <arm_group>
    <arm_group_label>Subjects Presenting With Normal Eyes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with no known ocular diseases will be scanned on the Maestro device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3D OCT-1 Maestro</intervention_name>
    <description>OCT Machine used for diagnostic purposes</description>
    <arm_group_label>Subjects Presenting With Normal Eyes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Participants must be at least 18 years of age

          2. They must be able to complete all testing (all OCT scans)

          3. They must volunteer to be in the study and sign the consent form

        Exclusion Criteria

          1. Subject with history of ocular disease or ocular pathology

          2. TopQ score from baseline OCT scan (i.e., without any ND filters) is below the cut-off
             value.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randy Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Topcon Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Topcon Medical Systems, Inc.</name>
      <address>
        <city>Oakland</city>
        <state>New Jersey</state>
        <zip>07436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2015</study_first_posted>
  <results_first_submitted>July 14, 2016</results_first_submitted>
  <results_first_submitted_qc>December 5, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 31, 2017</results_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>no known ocular pathology</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects Presenting With Normal Eyes</title>
          <description>Subjects with no known ocular diseases will be scanned on the Maestro device
3D OCT-1 Maestro: OCT Machine used for diagnostic purposes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Normal healthy eyes without any known eye conditions</population>
      <group_list>
        <group group_id="B1">
          <title>Subjects Presenting With Normal Eyes</title>
          <description>Subjects with no known ocular diseases will be scanned on the Maestro device
3D OCT-1 Maestro: OCT Machine used for diagnostic purposes</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.17" spread="13.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>TopQ Cut Off</title>
        <description>To validate the values of the predetermined TopQ score by showing the variability above and below the TopQ score of 25 for 12x9 Wide, 28 for 6x6 Macula, and 30 for 6x6 Disc scans.</description>
        <time_frame>1 hour</time_frame>
        <population>use of 12 subjects for 3 different scan patterns</population>
        <group_list>
          <group group_id="O1">
            <title>12x9 Wide Scan</title>
            <description>TopQ of 12x9 Wide Scan</description>
          </group>
          <group group_id="O2">
            <title>6x6 Macula Scan</title>
            <description>TopQ of 6x6 Macular Scan</description>
          </group>
          <group group_id="O3">
            <title>6x6 Disc Scan</title>
            <description>TopQ of 6x6 Disc Scan</description>
          </group>
        </group_list>
        <measure>
          <title>TopQ Cut Off</title>
          <description>To validate the values of the predetermined TopQ score by showing the variability above and below the TopQ score of 25 for 12x9 Wide, 28 for 6x6 Macula, and 30 for 6x6 Disc scans.</description>
          <population>use of 12 subjects for 3 different scan patterns</population>
          <units>microns</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Standard Deviation Above Threshold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94"/>
                    <measurement group_id="O2" value="1.5"/>
                    <measurement group_id="O3" value="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standard Deviation Below Threshold</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.54"/>
                    <measurement group_id="O2" value="13.67"/>
                    <measurement group_id="O3" value="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects Presenting With Normal Eyes</title>
          <description>Subjects with no known ocular diseases will be scanned on the Maestro device
3D OCT-1 Maestro: OCT Machine used for diagnostic purposes</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles Reisman</name_or_title>
      <organization>Topcon</organization>
      <phone>201-599-5283</phone>
      <email>CREISMAN@topcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

